The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Symptom management through electronic patient-reported outcome (ePRO)-based intervention in patients with breast cancer treated with abemaciclib: Primary results from the LIBRA study, a phase II randomized controlled trial.
 
Toshimi Takano
Honoraria - Chugai Pharma; Daiichi Sankyo; Lilly
 
Tetsu Hayashida
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; Pfizer
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly; Taiho Pharmaceutical (Inst)
 
Aiko Nagayama
Stock and Other Ownership Interests - Chugai Pharma; Chugai Pharma (I)
Honoraria - Daiichi Sankyo/UCB Japan; Pfizer
 
Yukinori Ozaki
Honoraria - Chugai Pharma; Daiichi Sankyo; Kyowa Kirin International; Lilly; Pfizer
 
Maiko Takahashi
No Relationships to Disclose
 
Tomoko Seki
No Relationships to Disclose
 
Takamichi Yokoe
Honoraria - AstraZeneca; Chugai/Roche; Daiichi Sankyo; Eisai; Kyowa Kirin
 
Yosuke Aoyama
No Relationships to Disclose
 
Rika Kizawa
No Relationships to Disclose
 
Meiko Nishimura
No Relationships to Disclose
 
Mari Hosonaga
No Relationships to Disclose
 
Fumikata Hara
Honoraria - Chugai Pharma; Daiichi Sankyo; Kyowa Kirin; Lilly Japan; MSD; Pfizer; Taiho Pharmaceutical
 
Takayuki Kobayashi
No Relationships to Disclose
 
Takayuki Ueno
Honoraria - AstraZeneca Japan; Chugai Pharma; Eisai; Novartis
Research Funding - Lilly Japan (Inst)
 
Yuko Kitagawa
Honoraria - Asahi Kasei; ASKA Pharmaceutical Co., Ltd.; AstraZeneca Japan; Bristol-Myers Squibb K.K.; Chugai Foundation for Innovative Drug Discovery Science; Chugai Pharma; DAIICHI SANKYO COMPANY, LIMITED; EA Pharma; Ethicon; Intuitive Surgical; Kaken Pharmaceutical; Miyarisan pharmaceutical; MSD K.K.; Nippon Covidien; Nippon Kayaku; Olympus; Ono Pharmaceutical; Otsuka; Shionogi; Smith & Nephew; Sysmex; Taiho Pharmaceutical; Toray Industries
Consulting or Advisory Role - Bristol-Myers Squibb K.K.; Ono Pharmaceutical
Research Funding - Asahi Kasei (Inst); Chugai Pharma (Inst); Eisai (Inst); Kaken Pharmaceutical (Inst); Kowa (Inst); Kyouwa Hakkou Kirin Co., Ltd. (Inst); Nippon Covidien (Inst); Otsuka (Inst); Otsuka (Inst); Sumitomo Pharma Co., Ltd. (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Teijin Pharma (Inst); TSUMURA & CO. (Inst)